AG1705
/ Ahn-Gook Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 17, 2022
Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS
(clinicaltrials.gov)
- P3 | N=306 | Not yet recruiting | Sponsor: Ahn-Gook Pharmaceuticals Co.,Ltd
New P3 trial • Cardiovascular • Hypertension
1 to 1
Of
1
Go to page
1